Table 1. Number of probe-sets differentially expressed in SLE patients and immunized healthy donors with yellow fever vaccine.
| Experimental group | Baseline group | Cell type | Total significant probes | IFN signature probesa | IFN signature probes (FCb ≥2 or ≤−2) |
| SLE (n = 6) | ND before immunizationc (n = 4) | CD4+ T cells | 3610 | 748 (20%) | 220 |
| Immunized NDd (n = 4) | ND before immunization (n = 4) | CD4+ T cells | 393 | 191 (49%) | 80 |
| SLE (n = 4) | ND before immunization (n = 4) | CD16− monocytes | 4222 | 982 (23%) | 342 |
| Immunized ND (n = 4) | ND before immunization (n = 4) | CD16− monocytes | 1534 | 540 (35%) | 149 |
| SLE (n = 4) | ND before immunization (n = 3) | CD16+ monocytes | 3785 | 881 (23%) | 312 |
| Immunized ND (n = 3) | ND before immunization (n = 3) | CD16+ monocytes | 1775 | 542 (31%) | 117 |
This table summarizes differentially expressed probe sets as obtained by comparing arrays of the experimental group versus baseline group. Indicated are the total number of differentially expressed probe sets, the number of overlapping IFN-associated genes (absolute number and percentage of total number of differentially expressed probe sets) and the number of IFN-associated genes with fold changes ≥2 or ≤−2.
a 2.442 interferon (IFN) signature genes were extracted from previous publications by Romos PS et al. [17] and Smiljanovic B et al. [11].
b FC: fold change.
c Expression data of healthy donors (ND) before immunization with yellow fever vaccine (YFV) was used as baseline for all comparisons.
d ND 7 days after immunization with YFV.